K020524

MAR 2 0 2002

510(k) Summary

This 510(k) Summary is submitted in accordance with 21 CFR 807.92.

Submitter's Name:

GE Medical Systems Information Technologies

Submitter's Address:

15222 Del Amo Avenue

Tustin, CA 92780

Telephone:

(800) 888-0777

Fax:

(714) 247-4155

Contact Person:

Diana M. Thorson

Date Prepared:

January 14, 2002

Device Trade Name:

PatientNet™ Monitoring System

Device Classification Name:

System, Network and Communication, Physiological Monitors

Device Classification:

Class II

Predicate Device(s):

VitalCom Networked Monitoring System

K962473

Device Description:

The modified PatientNet™ Monitoring System performs patient monitoring using PatientNet™ ambulatory radio transmitters or radio transmitters connected directly to bedside monitors or other digital bedside monitors with similar physiological parameters, and to ventilators that have digital outputs.

Intended Use:

The PatientNet™ System is intended to collect and analyze patient data from ECG ambulatory Transmitters/Transceivers, leading manufacturers' bedside monitors and ventilators anywhere in a healthcare facility and distributes the data to locations throughout the facility.

Performance Data:

The safety and effectiveness of the modified PatientNet™ Monitoring System described in this submission has been demonstrated through risk analysis and verification and validation testing. Test results demonstrated that the functionality and safety characteristics of the modified PatientNet™ Monitoring System are to the predicate device.

Conclusions:

Based on the information provided in this submission, the modified PatientNet™ Monitoring System is substantially equivalent to the predicate device and does not raise new issues of safety and effectiveness.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 2 0 2002

Ms. Diana M. Thorson Regulatory Affairs Manager GE Medical Systems Information Technology General Electric Company 15222 Del Amo Avenue Tustin, CA 92780

Re: K020524

Trade Name: PatientNet™ Monitoring System Regulation Name: Arrhythmia Detector and Alarm

Regulation Number: 21 CFR 870.1025 Regulatory Class: Class III (three)

Product Code: MHX
Dated: February 15, 2002
Received: February 19, 2002

Dear Ms. Thorson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 – Ms. Diana M. Thorson

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Acting Director

Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Page [of]

INDICATIONS FOR USE STATEMENT

510(k) Number:_	K020524	
Device Name:/	Patient Met Montoning	, system
Indications for U	lse:	
of ECG leads, bedside -Hospital areas that hav Station from the rooms -Clinical areas that hav frequency bands appro ECG leads, bedside mo Monitoring Station. Target Population: Those patients who are	ntrolled clinical setting that has mul monitors, or ventilators. ve the capability of installing hardwi or areas where bedside monitors of the capability of installing 174-216 ved by the FCC) to communicate v	or ventilators operate. 6 MHz radio systems (or alternate ia RF. The information from the via an RF transmitter to the Central
(PLEASE DO NOT WR	ITE BELOW THIS LINE - CONTINU	JE ON ANOTHER PAGE IF NEEDED
Со	Division of Cardiovascular & Respiratory Pevk	
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use